PHARMACOKINETIC-DYNAMIC RELATIONSHIP OF CISPLATIN IN-VITRO - SIMULATION OF AN IV BOLUS AND 3 H AND 20 H INFUSION

被引:39
作者
MA, J
VERWEIJ, J
KOLKER, HJ
VANINGEN, HE
STOTER, G
SCHELLENS, JHM
机构
[1] DR DANIEL DENHOED CLIN,ROTTERDAM CANC INST,DEPT MED ONCOL,EXPTL CHEMOTHERAPY & PHARMACOL LAB,3008 AE ROTTERDAM,NETHERLANDS
[2] DR DANIEL DAN HOED KLIN,ROTTERDAM CANC INST,DEPT CLIN CHEM,3008 AE ROTTERDAM,NETHERLANDS
关键词
D O I
10.1038/bjc.1994.166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 +/- 0.36; 3 h infusion, 6.35 +/- 0.59; and 20 h infusion, 6.76 +/- 0.40 mu g h ml(-1)). Also, the differences between the area under the CDDP-DNA adduct-time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.
引用
收藏
页码:858 / 862
页数:5
相关论文
共 23 条
[1]  
BAJORIN DF, 1986, CANCER RES, V46, P5969
[2]  
BENARD J, 1985, CANCER RES, V45, P4970
[3]  
FICHTINGERSCHEPMAN AMJ, 1987, CANCER RES, V47, P3000
[4]  
FORASTIERE AA, 1987, CANCER CHEMOTH PHARM, V19, P155
[5]   PHASE-I TRIAL OF A CISPLATIN-ALBUMIN COMPLEX FOR THE TREATMENT OF CANCER OF THE HEAD AND NECK [J].
HOLDING, JD ;
LINDUP, WE ;
VANLAER, C ;
VREEBURG, GCM ;
SCHILLING, V ;
WILSON, JA ;
STELL, PM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) :75-81
[6]  
JACOBS C, 1978, CANCER, V42, P2135, DOI 10.1002/1097-0142(197811)42:5<2135::AID-CNCR2820420508>3.0.CO
[7]  
2-W
[8]   PROLIFERATIVE DEFECTS IN RENAL AND INTESTINAL EPITHELIUM AFTER CIS-DICHLORODIAMMINE PLATINUM-(II) [J].
KOVACS, CJ ;
BRAUNSCHWEIGER, PG ;
SCHENKEN, LL ;
BURHOLT, DR .
BRITISH JOURNAL OF CANCER, 1982, 45 (02) :286-294
[9]   DRUGS 5 YEARS LATER - CISPLATIN [J].
LOEHRER, PJ ;
EINHORN, LH .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :704-713
[10]   INFLUENCE OF COMBINATION CHEMOTHERAPY WITH CIS-DIAMMINEDICHLOROPLATINUM ON RENAL-FUNCTION - LONG-TERM EFFECTS [J].
MEIJER, S ;
MULDER, NH ;
SLEIJFER, DT ;
DONKER, AJM ;
SLUITER, WJ ;
DEJONG, PE ;
KOOPS, HS ;
VANDERHEM, GK .
ONCOLOGY, 1983, 40 (03) :170-173